Observation on the effect of apatinib combined with S-1 as first-line treatment of advanced non-small cell lung cancer

Objective To explore the efficacy and safety of apatinib combined with S-1 in patients with advanced NSCLC without sensitive gene mutation or unknown mutation status. Methods One hundred and four patients with advanced NSCLC without sensitive gene mutation or unknown mutation status were selected from the oncology department of the First Hospital of Qinhuangdao City, Hebei Province from April 2015 to April 2017.All patients refused intravenous chemotherapy.One hundred and four patients were randomly divided into treatment group (apatinib combined with S-1 group) and control group (S-1 alone group) by 1: 1 digital method.However, two patients in the treatment group transferred to the control group for personal reasons.There is 50 cases in apatinib combined with S-1 group and 54 cases in S-1 group.The efficacy and adverse reactions of the two groups were evaluated. Results The objective remission rate was 48.0% (24/50) and 27.8% (15/54) (χ2=4.530, P=0.033), the disease control rate was 82.0% (41/50) and 74.1% (40/54) (χ2=0.947, P=0.331), the median PFS was 6.6 months and 3.4 months (t=25.555, P=0.000), the median OS was 16.0 months and 10.5 months (t=59.439, P=0.000), respectively.The overall incidence of adverse reactions was 82.0% (41/50) and 70.4% (38/54) respectively (χ2=1.923, P=0.166), of which 18.0% (9/50) and 13.0% (7/54) were more than grade 3 respectively (χ2=0.506, P=0.477). There was no death caused by treatment-related adverse reactions in both groups. Conclusion Appatinib combined with S-1 capsule has good short-term and long-term efficacy in the treatment of advanced non-small cell lung cancer without gene mutation or unknown mutation.The adverse reactions are tolerable and can be used as first-line treatment for patients unwilling to receive intravenous chemotherapy. Key words: Non-small cell lung cancer; Apatinib; S-1 capsules